Clearside Biomedical
CLSD61
$1.08arrow_drop_up4.90%$0.05
Penny Stock
CLSD61
$1.08
arrow_drop_up4.90%Performance History
| Key Stats | |
|---|---|
| Open | $1.03 |
| Prev. Close | $1.02 |
| EPS | -0.45 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $81.91M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 0.96 | 1.08 |
| 52 Week Range | 0.65 | 2.12 |
| Ratios | |
|---|---|
| EPS | -0.45 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Clearside Biomedical (CLSD)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
- Headquarters
- Alpharetta
- Employees
- 36
- Exchange
- NASDAQ
Keep an eye on Clearside Biomedical
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Clearside Biomedical 's (CLSD) price per share?
The current price per share for Clearside Biomedical (CLSD) is $1.08. The stock has seen a price change of $0.05 recently, indicating a 4.9% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Clearside Biomedical (CLSD)?
For Clearside Biomedical (CLSD), the 52-week high is $2.12, which is 96.3% from the current price. The 52-week low is $0.65, the current price is 66.15% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Clearside Biomedical (CLSD) a growth stock?
Clearside Biomedical (CLSD) has shown an average price growth of -3.66% over the past three years. It has received a score of 17 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Clearside Biomedical as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Clearside Biomedical (CLSD) stock price performance year to date (YTD)?
As of the latest data, Clearside Biomedical (CLSD) has a year-to-date price change of -16.28%. Over the past month, the stock has experienced a price change of -4.85%. Over the last three months, the change has been 5.88%. Over the past six months, the figure is -20.59%. Looking at a longer horizon, the five-year price change stands at -14.29%.
help
Is Clearside Biomedical (CLSD) a profitable company?
Clearside Biomedical (CLSD) has a net income of -$32.48M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -8.43K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $8.23M, although specific revenue growth data is currently not available. The gross profit is $7.87M. Operating income is noted at -$24.84M. Furthermore, the EBITDA is -$25.66M.
help
What is the market capitalization of Clearside Biomedical (CLSD)?
Clearside Biomedical (CLSD) has a market capitalization of $81.91M. The average daily trading volume is 1.06, indicating the stock's liquidity and investor engagement.
News
SUPRACHOROIDAL DRUG DELIVERY
NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
WET AMD
CLINICAL PROGRAMS
Clearside Biomedical Opens Registration for Suprachoroidal - GlobeNewswire
CALENDAR OF EVENTS
PRODUCT / SERVICES ANNOUNCEMENT
MANAGEMENT STATEMENTS
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
NEWS
ANALYST COLOR
BIOTECH
EQUITIES
HEALTH CARE
PRICE TARGET
INITIATION
ANALYST RATINGS
MOVERS
TRADING IDEAS
GENERAL
Why Is Clearside Biomedical Stock Gaining Today?
CLINICAL STUDY
Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting
HEALTH
OTHER NEWS
PRODUCT / SERVICES ANNOUNCEMENT
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®
May 9, 2024
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates